Amino acids in each: BPC-157 is 15, TB-500 is 7. Identity facts, not product claims.
Published BPC-157 and TB-500 researchPlain-English research guideBPC-157 / TB-500
BPC-157 and TB-500 research guide
Everything worth knowing, without the jargon.
This blend pairs BPC-157 and TB-500 in one vial. Both are studied in tissue-repair research; their research histories are described separately here. Neither is an approved medicine. One 2026 rat study (Biçer et al., 2026) included both, and this set makes no combined claim.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
REV 2026-10 · 1 Oct 20264 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
Year of a rat study that included both compounds. This guide draws no combined claim from it.
Biçer et al., 2026When the BPC-157 story began (a protective substance in gastric juice was described).
Sikiric et al., 1993When the TB-500 story began (the parent protein thymosin beta-4 was sequenced).
Low et al., 1981Why it matters
Why are BPC-157 and TB-500 studied?
BPC-157 and TB-500 are studied together in this set because both come up in tissue-repair research, but they are unrelated compounds with separate histories. BPC-157 is based on a partial sequence of a protective protein in gastric juice, and TB-500 is a small active piece of the protein thymosin beta-4. Both are studied almost entirely in cells and animals. One 2026 rat study (Biçer et al., 2026) included both; this guide draws no combined claim from it.
Two research stories, kept apart.
BPC-157 and TB-500 are offered together because both come up in tissue-repair research - but they're unrelated compounds with separate histories. BPC-157 is based on a partial sequence of a protective protein in gastric juice; TB-500 is a small active piece of the protein thymosin beta-4.
What they share is where the evidence sits: almost entirely in cells and animals, with no completed human trials of either. Their research stories stay separate: one 2026 rat study (Biçer et al., 2026) included both, and this set makes no combined claim from it.
Study observations
What laboratory observations have BPC-157 and TB-500 studies reported?
Chang et al. (Journal of Applied Physiology, 2011) reported tendon-cell and rat-tendon observations for BPC-157. Philp et al. (Wound Repair and Regeneration, 2003) reported wound-repair observations for a TB-500-type short fragment in mice. These separate cell and animal studies do not establish a combined clinical outcome for BPC-157 and TB-500 in the listed blend.
Separate BPC-157 and TB-500 records Findings stay tied to the cited study and its model.
BPC-157 cell and rat models
Chang et al. (Journal of Applied Physiology, 2011) reported tendon-cell growth and migration in culture and tendon-healing observations in rats.
TB-500-type fragment in mice
Philp et al. (Wound Repair and Regeneration, 2003) reported wound-repair observations for a short fragment in mice; this is separate from the BPC-157 findings.
Combined evidence limit
The separate cell and animal findings in Chang et al. (2011) and Philp et al. (2003) do not establish a combined clinical outcome for this blend.
Pharmacology at a glance
- Research code
- BPC-157 (GEPPPGKPADDAGLV) + TB-500 (Ac-LKKTETQ)
- Class
- Two separate synthetic research peptides studied in tissue-repair research - supplied together, not as a combined drug.
- Molecule
- BPC-157 is a 15-amino-acid peptide based on a partial sequence of a gastric-juice protein; TB-500 is the seven-amino-acid actin-binding fragment of thymosin beta-4. Two distinct compounds.
- Reported half-life
- BPC-157 had a short half-life (under about 30 minutes) in a rat and dog study; TB-500's is not established in humans.
- Originator
- BPC-157 came from a University of Zagreb group (1990s); the thymosin beta-4 protein behind TB-500 was sequenced in 1981, and the fragment characterised in 2012.
- Approval status
- Neither is an approved medicine anywhere; both are on the World Anti-Doping Agency prohibited list. Preclinical research compounds.
What it has been studied for
What have BPC-157 and TB-500 been studied for?
BPC-157 and TB-500 are covered in four areas: BPC-157 tissue repair, with tendon work (Chang et al., Journal of Applied Physiology, 2011) and blood-vessel work (Hsieh et al., Journal of Molecular Medicine, 2017), TB-500 as the actin-binding fragment of thymosin beta-4 (Van Troys et al., The EMBO Journal, 1996), the preclinical nature of the evidence for both, and combination research. All cited studies are preclinical; Biçer et al. (2026) included both in rats, with no claim drawn.
Study areas from the published literature.
BPC-157 - tissue & gut repair
Gut, tendon and blood-vessel repair, in rats and cell cultures.
Chang et al., 2011; Hsieh et al., 2017TB-500 - the actin-binding fragment
The part of thymosin beta-4 the fragment copies, and wound-repair work (mostly on the full protein).
Van Troys et al., 1996; Philp et al., 2003Both - preclinical only
Neither has completed human trials; the evidence is lab and animal.
Published researchBoth together - one rat study
One 2026 rat study included both; this guide draws no outcome from it.
Biçer et al., 2026The studies
What did the BPC-157 and TB-500 studies find?
The four studies behind the BPC-157 and TB-500 set are preclinical. Chang et al. (Journal of Applied Physiology, 2011) reported that BPC-157 tendon cells grew and migrated more and that rat tendons healed faster. Hsieh et al. (Journal of Molecular Medicine, 2017) linked BPC-157 to more new-vessel growth. Van Troys et al. (The EMBO Journal, 1996) identified the actin-binding region behind TB-500, and Philp et al. (Wound Repair and Regeneration, 2003) tested a TB-500-type short fragment in mice.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
A tendon-repair study on cultured tendon cells and a cut Achilles tendon in rats.
- Studied in
- Cultured rat tendon fibroblasts plus rats.
- Design
- A lab cell study alongside an animal tendon-healing model.
- Measured
- Cell growth and movement in the dish, and tendon healing in the rats.
The tendon cells grew and migrated more, and the rat tendons were reported to heal faster (Chang C-H and colleagues - Journal of Applied Physiology - 2011). Animal and cell results - not a claim about people (Chang C-H and colleagues - Journal of Applied Physiology - 2011).
DOI 10.1152/japplphysiol.00945.2010An angiogenesis (new-blood-vessel) study in cultured cells and a rat blood-flow model.
- Studied in
- Cultured human vascular cells plus rats.
- Design
- Lab cell experiments plus a rat hind-limb blood-flow model.
- Measured
- New-vessel growth and VEGFR2 signalling.
It linked BPC-157 to more new-vessel growth and VEGFR2 signalling in these models (Hsieh M-J and colleagues - Journal of Molecular Medicine - 2017). Cell and animal findings only (Hsieh M-J and colleagues - Journal of Molecular Medicine - 2017).
DOI 10.1007/s00109-016-1488-yA lab study that mapped the actin-binding region (residues 17-23) of thymosin beta-4 - the stretch TB-500 copies.
- Studied in
- Lab experiments with thymosin beta-4 and engineered variants.
- Design
- An in-vitro structure-function study.
- Measured
- Which residues were needed to bind actin.
It identified the region that became the TB-500 fragment (Van Troys M and colleagues - The EMBO Journal - 1996). It's about the whole protein, not the fragment product (Van Troys M and colleagues - The EMBO Journal - 1996).
DOI 10.1002/j.1460-2075.1996.tb00350.xThe closest genuine study of a TB-500-type short fragment: the seven-amino-acid actin-binding peptide tested in mice with slow-healing wounds.
- Studied in
- Mice (diabetic and aged models).
- Design
- An animal wound-healing model comparing the full protein and the short fragment.
- Measured
- How well wounds healed.
Philp et al. (Wound Repair and Regeneration, 2003) reported wound-repair observations for a TB-500-type short fragment in mice; this is an animal finding separate from the BPC-157 studies.
DOI 10.1046/j.1524-475X.2003.11105.xRisks recorded in studies
What risks have BPC-157 and TB-500 studies recorded?
The studies cited in this guide are preclinical, so they do not establish the human safety profile of BPC-157 or TB-500. For BPC-157, this guide records small uncontrolled pilot reports but no completed randomised controlled trial. One cited study, a rat study (Biçer et al., 2026), included both compounds, and this guide draws no safety or combined-use conclusion from it. Both are supplied here only as research materials.
Human safety isn't established for either
Not establishedNeither BPC-157 nor TB-500 has completed human trials, so their human safety profiles aren't established.
Combined evidence limit
A key caveatOne 2026 rat study (Biçer et al., 2026) included both, and this guide draws no conclusion about using them together from it - this set makes no such claim.
Banned in sport
RegulatoryBoth are on the World Anti-Doping Agency prohibited list, so neither is permitted for athletes.
Not approved medicines
RegulatoryNo medicines regulator has approved either compound for any use. They're supplied here only as research materials.
This section summarizes third-party trial records. It is not a complete safety profile or advice.
Where evidence stops
What has BPC-157 and TB-500 research not established?
No combined outcome for BPC-157 and TB-500 is summarised here; one rat study (Biçer et al., 2026) included both. For BPC-157 this guide records small uncontrolled pilot reports but no completed randomised controlled trial, and for TB-500 it cites no human trial; the cited studies do not establish long-term safety for either.
- The two combined: this guide summarises no combined outcome; one 2026 rat study (Biçer et al., 2026) included both.
- People: no completed human trials of either compound.
- Long-term safety: not established for either.
Development and status
Are BPC-157 and TB-500 approved, and where does the research stand?
BPC-157 and TB-500 are recorded in this guide's timeline as preclinical research compounds. The TB-500 story begins with the sequencing of thymosin beta-4 (Low et al., PNAS, 1981) and the BPC-157 story with a protective gastric-juice substance (Sikiric et al., Journal de Physiologie (Paris), 1993). This guide's timeline lists, for 2026, a first controlled BPC-157 trial (NCT07437547) beginning and a TB-500 safety study (NCT07487363) as recruiting, with no results recorded.
The parent protein behind TB-500, thymosin beta-4, is sequenced.
The protective gastric-juice substance behind BPC-157 is described.
Animal and cell studies: BPC-157 for gut/tendon/vessels; the thymosin beta-4 actin region is mapped.
The Ac-LKKTETQ 'TB-500' fragment is characterised.
A first controlled human trial of BPC-157 begins; a TB-500 safety trial is recruiting. Results are pending.
Approval status: Neither is an approved medicine anywhere; both are on the World Anti-Doping Agency prohibited list. Preclinical research compounds.Whatever the molecule’s status elsewhere, what Form Labs supplies is research-use-only reference material - for laboratory work, not for people or animals.
Evidence and limitations
What does the BPC-157 and TB-500 research mean, and what does it not?
The BPC-157 and TB-500 evidence cited in this guide is preclinical: it comes from cells and animals, and for TB-500 it is often on the parent protein rather than the fragment. Animal results often do not carry over to people, and one cited rat study (Biçer et al., 2026) included both, but this guide draws no combined-use conclusion from it. BPC-157's literature leans heavily on one originating group.
Both are preclinical
The evidence for each is in cells and animals, and often - for TB-500 - on the parent protein rather than the fragment. Animal results often don't carry over to people.
No combined outcome is drawn
One 2026 rat study (Biçer et al., 2026) included both compounds, and this guide draws no combined outcome from it. This set makes no combined claim.
Neither is settled science
BPC-157's literature leans heavily on one originating group; TB-500's direct fragment evidence is thin. Both are early-stage research areas.
Where Form Labs fits
This guide is a plain-English summary of published research Form Labs did not run. It's not medical advice, not a product claim, and not use guidance. We supply the set strictly as reference material, with catalog lot records. Matching current certification is unverified.
Lab handling
How are BPC-157 and TB-500 handled as reference material?
BPC-157 and TB-500 are laboratory reference material, not for human consumption or veterinary use. Storage and lot checks follow the product label and any verified matching certificate of analysis (COA). This guide's catalogue record notes storage at 2-8 C and protection from light. Historical sample reports do not verify current lot identity, purity or release status.
Research-use boundary
BPC-157 and TB-500 is supplied strictly for laboratory research. It is not for human consumption, veterinary, medical, or cosmetic use.
Storage
Supplied freeze-dried. Keep it at 2-8 C (fridge-cold) and out of light, following the vial label, any verified matching lab report for the batch, and your lab's own written procedures.
Glossary
Plain-English definitions.
- Peptide
- A short chain of amino acids.
- BPC-157
- A synthetic 15-amino-acid peptide based on a protective protein in gastric juice.
- TB-500
- A synthetic seven-amino-acid fragment of the protein thymosin beta-4.
- Thymosin beta-4
- A natural 43-amino-acid protein; TB-500 is a small piece of it.
- Preclinical
- Research in cells and animals, before trials in people.
- In-vivo
- In a living animal.
- Angiogenesis
- The growth of new blood vessels.
- Research use only
- Supplied for laboratory research - not for human or animal use, and not a medicine.
FAQ
What are the most common questions about BPC-157 and TB-500?
The BPC-157 and TB-500 blend contains two research peptides in one vial, with current matching certification unverified: BPC-157, a 15-amino-acid peptide, and TB-500, a seven-amino-acid fragment of thymosin beta-4 (Form Labs catalogue record). The most common questions about BPC-157 and TB-500 cover whether the two work together, how they are related, how strong the evidence is, whether they have been tested in people, and their Australian status.
The blend contains two research peptides in one vial, with current matching certification unverified: BPC-157 (a 15-amino-acid peptide, GEPPPGKPADDAGLV) and TB-500 (a seven-amino-acid fragment, Ac-LKKTETQ, of the protein thymosin beta-4). Two different compounds with two different research stories, supplied as a blend in one vial.
This guide makes no such claim. One 2026 rat study (Biçer et al., Joint Diseases and Related Surgery) included both BPC-157 and TB-500, and this guide draws no combined outcome from it. Each is otherwise researched on its own, in cells and animals, and this guide makes no combined or synergistic claim.
They aren't, biologically. BPC-157 is based on a partial sequence of a protein in gastric juice; TB-500 is a fragment of a different protein, thymosin beta-4. They share only a research theme - tissue repair - and are grouped as a set for that reason, not because they act alike or together.
Both are preclinical. BPC-157 has a large but single-group-dominated animal literature and no completed human trials. TB-500's own fragment evidence is thin - most of the well-known findings are on its parent protein, thymosin beta-4, not the fragment - and it also has no published human trials. Neither is settled science.
Not in completed, published trials. BPC-157's first controlled human trial (NCT07437547) began in 2026, with results expected around 2027; a TB-500 safety study (NCT07487363) is recruiting with no results. Today's evidence for both is almost entirely from cell and animal research.
Chang et al. (Journal of Applied Physiology, 2011) reported tendon-cell and rat-tendon findings for BPC-157. Van Troys et al. (The EMBO Journal, 1996) examined the parent protein's actin-binding region; Philp et al. (Wound Repair and Regeneration, 2003) reported mouse observations for a TB-500-type short fragment. These are separate preclinical records.
BPC-157 and TB-500 are both Schedule 4 substances in Australia. The October 2026 Poisons Standard (checked 1 October 2026) lists each in Schedule 4 and in Appendix D, clause 5 - the appendix for poisons whose possession without authority is illegal. The TGA's April 2026 examples of unapproved peptide products name both, and Sport Integrity Australia lists both as prohibited in sport. Form Labs supplies both strictly as laboratory research material, not for human or veterinary use.
Form Labs supplies peptides strictly as laboratory research materials. This guide is a plain-English summary of published research Form Labs did not run - not medical advice, not a product claim, and not guidance for any human or veterinary use.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
BPC-157 - foundational gastric-juice paper. Sikiric P, et al. Journal de Physiologie (Paris), 1993; 87(5): 313-327.
DOIBPC-157 - rat and cell tendon-healing study. Chang C-H, et al. Journal of Applied Physiology, 2011; 110(3): 774-780.
DOIBPC-157 - cell and rat angiogenesis study. Hsieh M-J, et al. Journal of Molecular Medicine, 2017; 95(3): 323-333.
DOITB-500 - mapping the actin-binding region of thymosin beta-4. Van Troys M, et al. The EMBO Journal, 1996; 15(2): 201-210.
DOITB-500 - mouse study of the short actin-binding fragment in wound healing. Philp D, et al. Wound Repair and Regeneration, 2003; 11(1): 19-24.
DOITB-500 - synthesis and characterisation of the Ac-LKKTETQ fragment. Esposito S, et al. Drug Testing and Analysis, 2012; 4(9): 733-738.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
These guides are written and maintained in-house by the Form Laboratories research team. They summarise published literature and link to the cited papers. Form Laboratories did not run those studies. They are not authored by a named clinician and are not medical advice.
Findings remain tied to the study population, model and limits. Cell and animal observations remain separate from clinical results. Everything we supply is research-use-only reference material, not for people or animals.
The product
Form Laboratories - BPC-157 & TB-500
Ready to see BPC-157 & TB-500?
- Check available reports and the tests they cover.
- Compare the listed compound, amount and lot with the report.
- Ships from Perth via Australia Post or CouriersPlease in plain packaging.
Related catalogue records
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View BPC-157 & TB-500 - from $119.00 AUD